Cover Image


Global Hypercholesterolemia Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 306286
出版日期 內容資訊 英文 82 Pages
Back to Top
全球高膽固醇症市場: Global Hypercholesterolemia Market 2014-2018
出版日期: 2014年06月06日 內容資訊: 英文 82 Pages



第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

  • 市場概要
  • 產品概要
    • 產品簡介

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 臨床實驗平台投資組合

第8章 各疾病市場區隔

第9章 各MOA市場區隔

第10章 全球Statin市場

第11章 各地區市場區隔

第12章 購買標準

第13章 推動市場成長要素

第14章 推動因素與其影響

第15章 市場課題

第16章 推動因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 供應商環境

  • 競爭模式
    • 最新資訊
    • 合併、收購
  • 市場分析
  • 其他值得注意的供應商
  • 預計開墾市場的未來供應商

第20章 本系列的報告介紹


Product Code: IRTNTR3588

About Hypercholesterolemia

Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as atherosclerosis and stroke. The normal physiological range of total blood cholesterol is 140-200 mg/dL. However, blood cholesterol consists of various individual components such as LDL cholesterol and HDL cholesterol. While LDL delivers cholesterol to the body, HDL removes cholesterol from cells by reverse cholesterol transport to the liver. Owing to their distinct roles, these components are separately taken into account to determine the dyslipidemic status of an individual. The inheritable form of hypercholesterolemia, characterized by elevated total cholesterol and LDL cholesterol levels, is known as familial hypercholesterolemia. When the condition is inherited due to the presence of one abnormal copy of the LDL receptor gene, it is known as heterozygous familial hypercholesterolemia. The presence of abnormal copies of both the LDL receptor alleles leads to homozygous familial hypercholesterolemia.

TechNavio's analysts forecast the Global Hypercholesterolemia market will grow at a CAGR of 3.81 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Hypercholesterolemia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hypercholesterolemia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • AbbVie Inc.
  • Astrazeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Aegerion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • AtheroNova Inc.
  • Incorporated
  • Bristol-Myers Squibb Company
  • Catabasis Pharmaceuticals Inc.
  • Cerenis Therapeutics, SA
  • CymaBay Therapeutics, Inc.
  • Daiichi Sankyo Inc.
  • Eli Lilly and Company
  • Esperion Therapeutics Inc.
  • Glaxosmithkline plc
  • Kadmon Pharmaceuticals LLC
  • Kowa Pharmaceuticals America Inc.
  • Laboratoires SMB S.A.
  • Madrigal Pharmaceuticals Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • REGENX BioSciences, LLC
  • Santaris Pharma A/S
  • Serometrix LLC
  • Shionogi Pharma Inc.
  • Spherix Incorporated
  • Sun Pharma USA
  • Tekmira Pharmaceuticals Corp.

Key Market Driver

  • Increase in the Incidence and Prevalence of Cardiovascular Diseases.

For a full, detailed list, view our report.

Key Market Challenge

  • Increase in Generic Erosion.

For a full, detailed list, view our report.

Key Market Trend

  • Fierce Market Competition.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Clinical Pipeline Portfolio

08. Market Segmentation by Type of Disease

09. Market Segmentation by MOA

10. Global Statins Market

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors
  • 19.4. Future Players Expected to Tap the Market

20. Key Vendor Analysis

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Hypercholesterolemia Market 2013-2018 (US$ billion)
  • Exhibit 3: Classification of Hyperlipidemia
  • Exhibit 4: Market Segmentation of Hypercholesterolemia Drugs by MOA
  • Exhibit 5: Market Share Segmentation on the Basis of MOA 2013
  • Exhibit 6: Number of Prescriptions for Cholesterol Lowering Classes in 2012 (in percent)
  • Exhibit 7: Number of Prescriptions for Statins in US (in 2012)
  • Exhibit 8: Number of Prescriptions for Non-Statins in US by (in 2012)
  • Exhibit 9: Global Statins Market 2013-2018 (US$ billion)
  • Exhibit 10: Global Hypercholesterolemia Market by Geographical Segmentation 2013
Back to Top